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The Hippo-signaling pathway is an important regu-
lator of cellular proliferation and organ size. However,
little is known about the role of this cascade in the
control of cell fate. Employing a combination of line-
age tracing, clonal analysis, and organoid culture
approaches, we demonstrate that Hippo pathway
activity is essential for the maintenance of the differ-
entiated hepatocyte state. Remarkably, acute inacti-
vation of Hippo pathway signaling in vivo is sufficient
to dedifferentiate, at very high efficiencies, adult
hepatocytes into cells bearing progenitor character-
istics. These hepatocyte-derived progenitor cells
demonstrate self-renewal and engraftment capacity
at the single-cell level. We also identify the NOTCH-
signaling pathway as a functional important effector
downstream of the Hippo transducer YAP. Our find-
ings uncover a potent role for Hippo/YAP signaling
in controlling liver cell fate and reveal an unprece-
dented level of phenotypic plasticity in mature
hepatocytes, which has implications for the under-
standing and manipulation of liver regeneration.
INTRODUCTION
The liver has a tremendous latent regenerative capacity. Within a
few days, 90%of the liver mass lost to a partial hepatectomy can
be restored by hepatocyte proliferation of the remaining liver
lobes. Under conditions of extreme stress or chronic injury, a
population of atypical ductal cells, usually referred to as ‘‘oval
cells,’’ emerges from the bile ducts and is thought to participate
in liver repair (Oertel and Shafritz, 2008; Turner et al., 2011).
These putative hepatic progenitor cells are able to differentiate
into hepatocytes and biliary cells as evidenced by lineage tracing
studies after injury (Espanol-Suner et al., 2012; Huch et al.,1324 Cell 157, 1324–1338, June 5, 2014 ª2014 Elsevier Inc.2013). However, the fate relationships between hepatocytes,
ductal cells, and progenitors are still unclear and highly debated
(Greenbaum, 2011; Michalopoulos, 2012). Also lacking is the
identification of signaling pathways that specify and maintain
progenitor fate within the liver.
The Hippo/YAP-signaling pathway is a critical regulator of liver
size (Camargo et al., 2007; Dong et al., 2007). Hippo pathway
signaling engagement results in phosphorylation and inactiva-
tion of the transcriptional coactivator YAP (Ramos andCamargo,
2012). Components of this signaling cascade include the tumor
suppressor NF2, the scaffoldingmoleculeWW45, theDrosophila
Hippo orthologs MST1/2, and their substrates, the kinases,
LATS1/2. YAP phosphorylation by LATS1/2 results in its cyto-
plasmic localization and proteolytic degradation (Oka et al.,
2008; Zhao et al., 2007). YAP exerts its transcriptional activity
mostly by interacting with the TEAD family of transcription fac-
tors and activating target gene expression (Wu et al., 2008;
Zhang et al., 2008). Manipulation of Hippo pathway activity leads
to profound changes in liver cell proliferation. YAP overexpres-
sion results in approximately a 4-fold increase in liver size within
weeks (Camargo et al., 2007; Dong et al., 2007). Additionally,
acute postnatal loss of Mst1/2 (Zhou et al., 2009), Nf2 (Benha-
mouche et al., 2010), and Ww45 (Lee et al., 2010) leads to
increased YAP levels, resulting in hepatomegaly and eventually
liver cancer. In most of these models, the presence of a large
number of atypical ductal cells has led to the prevailing view
that overgrowth in these models is mostly driven by the activa-
tion and expansion of putative progenitors (Benhamouche
et al., 2010). However, given that genetic manipulations in these
mice occurred in all liver populations (hepatocytes, ductal cells,
and progenitors), it is still unknown which cell types within the
liver respond to alterations in Hippo signaling. Furthermore, the
identity of the functional YAP transcriptional targets that drive
these responses remain to be elucidated.
Here, we demonstrate that Hippo/YAP signaling plays an
essential role by determining cellular fates in themammalian liver.
Elevated YAP activity defines hepatic progenitor identity and its
ectopic activation in differentiated hepatocytes results in their
dedifferentiation, driving liver overgrowth and ‘‘oval’’ cell appear-
ance. Our data identify the NOTCH-signaling pathway as one
important downstream target of YAP in liver cells. Our work also
uncovers a remarkable plasticity of the mature hepatocyte state.
RESULTS
YAP Is Enriched and Activated in the Biliary
Compartment
The identity of the Hippo-responsive cells within the liver is
unclear. To bring insight into this question, we analyzed Hippo
pathway signaling activity in the epithelial compartments of the
mammalian liver. YAP is expressed at high levels in bile ducts,
withmany ductal cells displaying robust nuclear YAP localization
(Figure 1A). YAP protein is detected at lower levels in hepato-
cytes (Li et al., 2011; Zhang et al., 2010), where the signal is
diffuse throughout the cell (Figure 1A). Immunohistochemical
(IHC) analysis of livers with a mosaic deletion of YAP confirms
this observation (Figure 1A, right panel). Immunoblot analyses
confirm higher levels of YAP protein in purified ductal cells and
also indicate a robust decrease in relative phospho-YAP levels
(Figure 1B). Gene expression analysis of isolated hepatocytes
versus sorted ductal cells further demonstrates amarked enrich-
ment of YAP/TEAD target genes, as well as of Yap1 itself, in the
ductal fraction (Figure 1C; Figure S1A available online).
To extend these observations, we generated mice with a bac-
terial artificial chromosome (BAC) knockin of EGFP in the con-
nective tissue growth factor gene (Ctgf) locus. Ctgf is the most
highly characterized YAP target gene (Lee et al., 2010; Lu
et al., 2010). In support of our staining data, we find that EGFP
expression is absent in hepatocytes and is restricted to a subset
of ductal cells expressing the markers CK19, SOX9, and A6 (Fig-
ure 1D), which have been historically associated with hepatic
progenitors and the ductal fate (Demetris et al., 1996; Dorrell
et al., 2011; Engelhardt et al., 1993). CTGF protein was also en-
riched in biliary cell lysates (Figure 1B), confirming enhanced
YAP transcriptional activity in this cellular compartment. Thus,
our results demonstrate that YAP activity and expression is high-
ly enriched in a subset of ductal cells expressing markers asso-
ciated with progenitor cells. On the other hand, mature hepato-
cytes display higher Hippo pathway activity as YAP nuclear
levels and transcriptional activity are reduced.
YAP Activation Induces a Ductal Fate in Hepatocytes
We then sought to evaluate the differential effects of Hippo/YAP
manipulation in hepatocytic and ductal/progenitor cellular com-
partments in vivo. These experiments would provide insight into
the nature of the cell type(s) that respond to YAP and are respon-
sible for liver overgrowth.
We first utilized a Ck19-CreERT driver to activate expression
of a doxycycline (Dox)-inducible version of human YAP carrying
an S127A mutation (TetOYAP; Figure S1B). This protein has
enhanced nuclear localization by escaping inactivation by
LATS1/2 (Zhao et al., 2007). Tamoxifen injection into mice fol-
lowed by Dox administration leads to mosaic activation of trans-
genic YAP (Figure S1B). Cells expressing the transgene can be
visualized given that the YAP antibody used has a much higher
affinity for human YAP. Two weeks post-Dox, YAP transgene-expressing (Tg) CK19+ cells appeared to take on a rounded
morphology that distinguished these cells from the remainder
of the cuboidal biliary epithelium (Figure S1B). Four and eight
weeks post-Dox, larger groups of cells appeared to grow within
the ductal epithelium, occasionally forming multilayered struc-
tures (Figure S1B). Because putative liver progenitors are known
to express CK19, we hypothesized that YAP expression would
expand such a cell population and mimic an atypical ductular re-
action, where progenitors exit out of the portal area and enter
into the hepatic parenchyma (Demetris et al., 1996). No such
cells were identified, suggesting that expression of activated
YAP in the biliary/progenitor compartment results in ductal
hyperplasia but does not result in progenitor activation or in their
entry into the hepatocyte compartment.
Directed hepatocyte-specific activation of YAP was achieved
by administering a Cre-expressing adenoassociated virus (AAV-
Cre) to TetOYAP mice (Figure 1E). AAV2/8 preferentially targets
hepatocytes and is currently the method of choice for gene de-
livery to this cell type (Fan et al., 2012; Malato et al., 2011).
Furthermore, this vector’s cell-type specificity was improved
by using a liver-specific promoter to drive Cre (Tanigawa et al.,
2007). We validated the hepatocyte specificity of this virus by
immunofluorescence examination of tissues (Figure S1C) and
by fluorescence-activated cell sorting (FACS) analysis of isolated
hepatocyte and ductal fractions (Figure S1D). Additionally, we
generated liver organoids from Cre-reporter mice infected with
AAV-Cre to determine if any organoid-forming progenitors would
be infected with the virus (Huch et al., 2013) (Figure S1E). Com-
bined, these analyses confirmed the previously reported hepato-
cyte specificity of AAV-Cre, although it suggested that an
extremely low fraction (0.2%–0.5%) of progenitors/ductal cells
could be infected at high AAV-Cre doses.
TetOYAP mice that were exposed to AAV-Cre, but were not
given Dox, had normal appearing livers (Figure 1F). In contrast,
AAV-Cre-treated TetOYAP mice given Dox for 3 weeks had a
rapid increase in liver growth (Figures 1F and S1F). Surprisingly,
histological analyses of +Dox livers revealed the widespread
appearance of small cells with scant cytoplasm, to the extent
that up to 80% of the liver was composed of this cell population
(Figure 1F). This cellular morphology was highly reminiscent of
putative progenitors associated with typical ductular reactions.
IHC characterization of Tg livers revealed strikingly broad
expression of the ductal markers pan-cytokeratin (panCK) and
HNF1b (Figure 1G). Additionally, liverswere overwhelmingly pos-
itive for SOX9 (Figure 1G), whose expression was initially more
prominent around portal as compared to central venous areas
(Figure S1G). Likewise, the initial wave of proliferation was pri-
marily centered on portal areas as identified by phospho-Histone
H3 staining (Figure S1H). Overall, our data suggest that YAP
activation in hepatocytes leads to overgrowth and the emer-
gence of cells bearing characteristics of ductal/progenitor cells.
In contrast, YAP activation in the ductal compartment cells leads
to hyperplasia, but not to an oval-cell-like appearance.
YAP Activation Dedifferentiates Single Adult
Hepatocytes
Our data above could be explained by two possibili-
ties: either YAP activation dedifferentiates hepatocytes intoCell 157, 1324–1338, June 5, 2014 ª2014 Elsevier Inc. 1325
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Figure 1. Hepatocyte-Specific YAP Expression Results in Ductal/Progenitor Marker Expression
(A) YAP protein/activity is enriched in a subset of ductal cells. Control (Ctl) liver YAP staining (4003) shows prominent signaling in bile ductules. Arrowheads
indicate ductal cells with nuclear YAP (inset shows magnified view). Yapfl/fl mice given Ad-Cre recombinase (Ad-cre Yapfl/fl) demonstrate patchy YAP staining in
hepatocytes (1003).
(B) Immunoblots of human hepatocyte (Hep) and biliary (Bil) lysates for YAP, pYAP, CTGF, and b-actin.
(C) Quantitative real-time PCR comparing relative levels of YAP and YAP targets in hepatocytes (Hep) and biliary cells (BC). n = 3; mean ± SEM.
(D) Ctgf-EGFP mice show EGFP costaining (Ctgf) in a subset of CK19, SOX9, and A6-expressing cells.
(E) Experimental design for hepatocyte-specific YAP overexpression.
(F) Hematoxylin and eosin (H&E) of uninduced (Dox) or YAP Tg mouse (+Dox) for 21 days following injection with 1011 plaque-forming units (pfu) of AAV-Cre.
Right image displays a magnification of inset.
(G) Representative immunohistochimical stains of portal areas for YAP, panCK, SOX9, and HNF1b for the mice displayed in (F). *p < 0.05; ***p < 0.001.
See also Figure S1.
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progenitor/ductal-like cells or YAP activation leads to recruit-
ment and/or expansion of a progenitor/ductal population. To
distinguish between these two possibilities, we titrated the viral
titer down such that individual hepatocytes could be infected
and fate mapped for months without interference from neigh-
boring clones (Figure 2A). Additionally, for many of these exper-
iments, we utilized a Cre-dependent reporter to faithfully assess
the cell autonomy of this phenotype. Microscopic examination of
mouse livers given low-dose AAV-Cre revealed that single hepa-
tocytes upon YAP activation gradually become smaller and
adopt an oval morphology before multiplying and forming large
ductular structures (Figure 2A). These clusters costain for YAP,
the ductal markers panCK and CK19, and validated progenitor
markers, such as SOX9, MIC1C3, and A6 (Figure 2B) (Dorrell
et al., 2011; Engelhardt et al., 1993). Furthermore, we noted on
a regular basis, that these biliary structures were tightly associ-
ated with nontransgenic mesenchyme (Figure S2A). No similar
structures were observed in control animals.
To further strengthen these observations, we simultaneously
followed the expression of the hepatocyte marker HNF4a and
panCK in YAP-expressing clones. These were also lineage
traced with a Cre-dependent EYFP reporter (R26-lsl-EYFP). As
expected, all EYFP+ clones, prior to YAP induction were
HNF4a+ and panCK, confirming the hepatocyte-specific
tropism of AAV-Cre (n = 172; Figure 2C). One week after YAP
induction, multiple EYFP+ clones (36%, n = 388) could be iden-
tified that were double positive for panCK and HNF4a. Interest-
ingly, many of these clones were still composed of single cells,
indicating that cell division is not necessary for the initiation of
dedifferentiation (Figure 2C). These hybrid cells appeared like
neighboring hepatocytes in size and shape, suggesting a transi-
tional state. Moreover, a smaller number of clones had extin-
guished hepatic gene expression and were solely panCK+
(7%). After Dox administration for 4 weeks, more than 75% of
clones were either panCK+ only or contained panCK+/HNF4a+
cells (Figure 2Ci). A complementary quantitative analysis
measuring the identity of all transgenic cells, as opposed to
clonal output, demonstrates that more than 95% of EYFP+ cells
at 4 weeks were panCK+ only (Figure 2Cii). A similar transitional
state and clonal fate was observed when costaining for EYFP/
HNF4a/SOX9 (Figure S2B). Altogether, our results demonstrate
that high levels of YAP are sufficient to impose a ductal/progen-
itor-like fate on adult hepatocytes in a cell-autonomous manner.
These data also highlight that approximately 75% of adult hepa-
tocytes have the capacity to undergo this fate change in vivo.
Hippo Pathway Signaling Misregulation Results
in Hepatocyte Dedifferentiation
We next asked whether changes in endogenous hepatocyte Hip-
po pathway signaling could lead to hepatocyte dedifferentiation.
NF2 is a known potent negative regulator of YAP (Hamaratoglu
et al., 2006), and ablation of Nf2 in all liver cell types results in he-
patocellular carcinoma and cholangiocarcinoma (Benhamouche
et al., 2010; Zhang et al., 2010). Thus, we surmised that hepato-
cyte-specificNf2 losswould result in liver overgrowthandhepato-
cyte dedifferentiation intobiliary/progenitor cells asobservedwith
our TetOYAP model (Figure 3A). Two months following AAV-Cre
administration to Nf2fl/fl mice, we observed ductular structureshighly reminiscent of the clusters observed in the TetOYAPmodel
(Figure 3B). Similar to the YAP Tgmodel, progenitor/ductal struc-
tures in the Nf2mutant livers stained prominently for YAP, SOX9,
andpanCK (Figure 3C). Additionally, lineage tracingwith an induc-
ible b-galactosidase reporter revealed that such ductular clusters
were derived from AAV-Cre-transduced cells (Figure 3B, inset).
These data support our hypothesis that changes in endogenous
Hippo pathway signaling can reprogram hepatocytes into ductal
cells bearing characteristics of hepatic progenitors.
YAP Expression Activates a Liver Progenitor Cell
Program
To understand the molecular basis of YAP-mediated dedifferen-
tiation, and to bring insight into the molecular identity of YAP Tg
cells, we isolated EYFP+ cells at multiple time points upon Dox
induction and performed FACS purification followed by microar-
ray analysis (Figure 4A). As expected, we observed awidespread
and progressive silencing of the hepatocyte phenotype and a
gradual acquisition of genes associated with embryonic liver
development and ductal/progenitor features (Figures 4B and
S3A). Gene set enrichment analysis (GSEA) demonstrates that
a gene signature corresponding to endogenous liver progenitors
strongly correlated with YAP transgenic cells (Figure S3B). YAP
activation does not simply lead to hyperplastic response as no
enrichment was found when compared to a gene signature
derived from livers recovering from partial hepatectomy (Fig-
ure S3C). Our analysis also revealed several upregulated gene
programs that define the reprogramming process, including
those associated with NOTCH, TGFb, and EGFR signaling (Fig-
ure 4C). This analysis supports the notion that YAP expression
in hepatocytes extinguishes hepatocyte-specific gene expres-
sion and leads to the specific acquisition of a molecular state
resembling endogenous liver progenitors.
Reintroduction of Hippo Pathway Signaling Induces
Differentiated Fates in Reprogrammed Hepatocytes
Our results above suggest that YAP activation in hepatocytes
dedifferentiates them into cells that morphologically, phenotyp-
ically, and molecularly resemble putative hepatic progenitors.
These data support the idea that elevated YAP activity imposes
a progenitor state and raises the possibility that reduction of YAP
levels in liver progenitors could allow for their differentiation. We
thus investigated whether hepatocyte-derived progenitor-like
cells obtained after 4 weeks of YAP expression could give rise
to mature hepatocytes in situ, following the cessation of Dox
administration (Figure 4D).
Corroborating our previous data, 4 weeks post-Dox adminis-
tration, more than 98% of EYFP+ cells were panCK+ with typical
ductal morphology and marked mesenchymal recruitment (Fig-
ures 4D and 4E). Following Dox removal (chase period), EYFP+
cells could still be found throughout the liver parenchyma at 4
and 8weeks (Figure 4E). Although themajority of the EYFP+ cells
(80%) retained a ductal morphology and phenotype, removal
of Dox clearly resulted in the emergence of clusters of EYFP+
cells with mature hepatocyte morphology (Figure 4D), which ex-
pressed HNF4a but lacked expression of panCK and SOX9 (Fig-
ure 4E). Our analysis demonstrates that approximately 20% of
EYFP+ cells showed a hepatocyte phenotype following theCell 157, 1324–1338, June 5, 2014 ª2014 Elsevier Inc. 1327
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Figure 2. Clonal Analysis of YAP-Mediated Dedifferentiation
(A) Low-dose (108 pfu) AAV-Cre and Dox administration allows clonal tracking of hepatocytes expressing YAP for several weeks. Representative images of clonal
events at 1, 2, 4, and 8 weeks post-Dox (1003).
(B) Eight weeks post-Dox single hepatocytes give rise to ectopic ductal structures showing expression of multiple progenitor/biliary markers.
(legend continued on next page)
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Figure 3. Hepatocyte-Specific Nf2 Loss Results in Progenitor/Ductal Dedifferentiation
(A) Experimental design for generating hepatocyte-specific Nf2 loss.
(B) Representative H&E stains ofNf2-deficient (Mut) livers 2months after AAV-Cre administration. Inset shows a LacZ-stained nodule from anNf2mutant mouse.
(C) Stained serial section of a biliary malformation for YAP, SOX9, panCK, and Vimentin from an Nf2 mutant mouse 2 months after AAV-Cre.chase, compared to only 1.5% observed in the presence of
Dox. Thus, hepatocyte-derived progenitors can redifferentiate
into the hepatocyte lineage when normal Hippo pathway
signaling is re-established in vivo.
Hepatocyte-Derived Progenitors Are Clonogenic
To assess progenitor activity in the liver, we utilized a recently
developed liver organoid culture system (Figure S4A). Consistent
with this report, epithelial organoid structures express ductal
progenitor markers but lack hepatocyte gene expression (Fig-
ures 5CWT and S4B) (Huch et al., 2013). Interestingly, liver orga-
noids endogenously demonstrate high YAP activity, displaying
significant enrichment for a recently described YAP gene signa-
ture (Figure S4C) (Mohseni et al., 2014).
We next examined if hepatocyte-derived progenitor-like cells
exhibit clonogenic capacity. Whole-dissociated liver cells from
AAV-Cre-infected TetOYAP/R26-lsl-EYFP mice given Dox for
3 weeks were cultured in organoid media (Figure 5A). Strikingly,
hepatocyte-YAP activation results in a striking improvement in
organoid number compared with control AAV-infected Dox-
uninduced mice (Figure 5B). This effect is also observed when
similar epithelial cell numbers are plated (Figure S4D). Impor-
tantly, Tg organoids were overwhelmingly EYFP+, indicating
their hepatocyte origin, which contrasts with the EYFP, biliary
origin of control organoids (Figures 5B and S1E). Enhancement
progenitor output was evident in cultures grown both in the pres-(C) Clonal and dynamic analysis of fate change driven by YAP. Representative im
following YAP expression. Arrowhead indicates weak HNF4a staining. Bar grap
HNF4a only, HNF4a/panCK, or panCK only in clones or individual cells within
associated analysis.
See also Figure S2.ence and in the absence of Dox (Figures 5B and S4D), demon-
strating that organoid identity and growth are independent of
expression of the transgene. Hepatocyte-derived organoids
displayed immunochemical markers in a similar pattern to WT
organoids (Figure 5C). Hierarchical clustering and differential
gene expression analysis demonstrated that hepatocyte-
derived progenitors are closely related to WT organoids and
not to hepatocytes (Figures 5D and 5E). Interestingly, upregula-
tion of fetal hepatoblast markers Afp and Prox1 is observed in
hepatocyte-derived, but not in control, organoids (Figure S4F),
suggesting potentially that YAP might lead to the activation of
an embryonic-like progenitor phenotype. Additionally, hepato-
cyte-derived organoids are highly enriched for an endogenous
liver progenitor gene signature (Figure S4E; p < 0.001). In addi-
tion, many of the upregulated signaling programs we identified
in vivo (Figure 4C) were also found enriched in hepatocyte-
derived organoids (Figure S4I).
To conclusively assess the self-renewal, differentiation, and
engraftment capacity of hepatocyte-derived progenitors, we
generated organoids from single-sorted EYFP+ cells from
AAV-Cre/Dox-treated TetOYAP/R26-lsl-EYFP mice (Figure 5F).
Following single-cell sorting, clonal expansion was carried out
in a monolayer, as YAP expression allowed growth and mainte-
nance of the progenitor state in this context (Figures 5G, S4G,
and S4H). Addition of a NOTCH inhibitor and Dox withdrawal
to these cultures led to suppression of the biliary/progenitorages and quantitation of hepatocyte to progenitor/ductal cell dedifferentiation
hs represent measurements of cellular fates as examined by the presence of
clones. Table indicates number of mice, clones, and cells examined for the
Cell 157, 1324–1338, June 5, 2014 ª2014 Elsevier Inc. 1329
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Figure 4. Molecular Characterization of Dedifferentiated Hepatocytes and Consequences of Restoring Endogenous Hippo Pathway
Signaling
(A) Schematic representation of EYFP+ cell isolation from induced TetOYAP mice. Representative FACS plot 1 week after Dox administration is shown.
(B) Heatmap of 6,536 rank-ordered differentially expressed genes from microarray experiments from hepatocytes (control) and sorted EYFP+ hepatocytes
expressing YAP for 1 or 6 weeks. Hepatocytic, biliary, and YAP target genes are indicated to the right.
(C) Heatmap of 1,762 genes grouped by transcriptional gene program using Mclust. Annotated transcriptional programs of interest are noted to the right.
(D) Experimental design for the evaluation of fate outcomes following Dox removal in hepatocytes exposed to Dox for 4 weeks. EYFP stains of representative
slides from TetOYAPmice given AAV-cre, placed on Dox for 4 weeks (YAP Tg) and following a 4 or 8 week Dox wash period (YAP Tg + Chase, 2003). Arrowheads
indicate EYFP+ cells with hepatocyte morphology.
(E) Triple stain of a representative image (2003) (4 week on, 4 week chase) showing HNF4a (green), panCK (red), EYFP (white), and merge picture. Dot plot of
average number of EYFP+ cells for the indicated staining patterns and representative treatments. Horizontal line and number represents the mean. One-way
ANOVA was performed using the Kruskal-Wallis test.
See also Figure S3.
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fate and emergence of hepatocytic cells (Figure 5H). We next
evaluated the in vivo engraftment potential of hepatocyte-
derived progenitor clones by transplanting them into fumarylace-
toacetate hydrolase-deficient (Fah/) mice. Fah deficiency
results in liver failure unless mutant mice are administered 2-[2-
nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione (NTBC)
(Grompe et al., 1995). Differentiated cells derived from a progen-
itor clone were injected intrasplenically into Fah/ mice
(Figure 5F), and 4–5 months posttransplantation donor cell
engraftment was assessed by IHC. Remarkably, three out of
four recipient mice displayed evidence of widespread repopula-
tion (>60%) by EYFP+ cells (Figure 5I). EYFP+ clusters stained
positive for FAH and HNF4a and negative for CK19 (Figure 5I),
indicating an acquisition of a mature hepatocyte phenotype.
Our results are similar to the extent of repopulation typically
observed upon transplantation of freshly isolated hepatocytes
(Figure S4J). These results highlight the capacity of hepato-
cyte-derived progenitors to be amplified and to undergo rediffer-
entiation into hepatocytes at the single-cell level. Overall, our
data suggest that YAP activation in mature hepatocytes is suffi-
cient for imposing a molecular and bona fide functional progen-
itor state.
NOTCH Signaling Downstream of YAP during
Reprogramming
In our bioinformatic analysis of pathways activated in response
to hepatocyte-specific YAP expression, we found several upre-
gulated developmental cascades that could explain some of the
phenotypes observed (Figures 4C and S4I). The most upregu-
lated pathway in vivo and in vitro was NOTCH signaling. This
pathway is known to be an important determinant of biliary cell
fate and growth during embryogenesis (Hofmann et al., 2010;
Zong et al., 2009). Quantitative real-time PCR of EYFP+-sorted
cells 1 week after YAP activation confirmed striking upregulation
of several members of the NOTCH pathway, including Notch1/2,
Jag1, and the NOTCH target genes Hes1 and Sox9 (Figure 6A).
Immunostaining for HES1 confirmed NOTCH pathway activation
in YAP-expressing hepatocytes (Figure 6B). We next investi-
gated whether some of these NOTCH genes are direct transcrip-
tional targets of the YAP/TEAD complex. Analysis of published
genome-wide chromatin occupancy revealed significant enrich-
ment of TEAD4 in the promoter regions of Notch2 and Sox9 in
mouse trophoblast stem cells (Home et al., 2012). We validated
the presence of TEAD4 binding in these regions using chromatin
immunoprecipitation (ChIP) in dedifferentiated hepatocytes and
also demonstrated robust binding of YAP (Figure 6C). Further-
more, analysis of human ChiP-Seq data for TEAD4 in human
HepG2 cells exposed conserved regions of occupancy in both
NOTCH2 and SOX9 (Figure S5A). TEAD4 and YAP binding in
these regions was confirmed by ChIP-PCR (Figure S5A). We
focused on the bound region of Notch2 as YAP/TEAD binding
to this region displayed the highest signal-to-noise ratio. Addi-
tionally, NOTCH2 is the critical mammalian NOTCH receptor
involved in ductal development (Geisler et al., 2008; McCright
et al., 2002). We found two TEAD consensus binding sites in a re-
gion 750–1,150 bp downstream of the Notch2 transcriptional
start site. This region was cloned into a luciferase reporter
plasmid to evaluate its responsiveness to YAP/TEAD. Expres-sion of YAPS127A drastically increased luciferase activity in
cholangiocarcinoma cells, whereas YAPS94A, a YAP mutant
unable to bind TEAD proteins (Zhao et al., 2008), had no effect
on reporter activity. As predicted, mutation of the TEAD binding
sites in the Notch2 promoter region abrogates the YAPS127A-
driven increase in luciferase expression (Figure 6D), indicating
a functional role for these elements in driving Notch2 gene
expression. In support of YAP being important for the expression
of Notch2, Ad-Cre-mediated deletion of Yap and its homolog
Taz in liver organoids derived from Yapfl/fl/Tazfl/fl conditional
knockoutmice results in an acute and significant downregulation
of Notch2 transcript levels (Figure 6E). Similarly, YAP/TAZ
knockdown in human cholangiocarcinoma cells results in
50%–75% reduction of Notch2 mRNA (Figure S5B). Thus, our
results suggest that YAP/TEAD directly regulates transcription
of Notch2 and other NOTCH pathway genes to modulate
NOTCH signaling.
Finally, we sought to examine the functional role of NOTCH
signaling downstream of YAP in vivo. Despite the many NOTCH
receptors, NOTCH signaling is mediated through a single tran-
scriptional coactivator, RBPJ. We generated TetOYAP mice
also carrying a conditional Rpbj andmT/mG reporter alleles (Fig-
ure 7A), which were then treated with AAV-Cre followed by Dox
treatment. Control experiments demonstrated high-efficiency
Rbpj deletion exclusively in the hepatocytic compartment of
injected mice (Figure S6B). At high doses of AAV-Cre, deletion
of Rbpj dampened the appearance of small ductal-looking cells
and overall liver hyperplasia (Figure S6A), and significantly
reduced the number of CK19- and JAG1-positive cells emerging
2 weeks following Dox treatment (Figure 7B). Ck19 and Jag1 are
not considered RPBJ transcriptional targets. Even more striking
observations were made in the low-dose context, where clonal
outputs could be measured and evaluated at longer time points.
These experiments demonstrate that NOTCH inhibition resulted
in a significant and drastic reduction in the size of dedifferenti-
ated clones (Figure 7C). Additionally, the vast majority of Rbpj-
mutant clusters exhibited poorly developed biliary morphology
and absent mesenchymal recruitment (Figures 7C and 7D).
Clonal analyses revealed that fate outputs of YAP-expressing
hepatocytes were altered in the absence of NOTCH signaling,
as only 25% of clones were CK19+/HNF4a compared
to >97% of control clones at 12 weeks of induction (Figure 7D).
Single transcript in situ hybridization confirmed reduction of
mRNA in Rbpj mutant clones (Figure S6C). Altogether, these
data provide evidence that Hippo/YAP act upstream of the
NOTCH-signaling pathway, whose activity is important for hepa-
tocyte-to-ductal dedifferentiation and clonal outgrowth.
DISCUSSION
The fate relationship among hepatocytes, ductal cholangio-
cytes, and putative liver progenitors is amatter of debate (Green-
baum, 2011; Michalopoulos, 2012). Whereas lineage tracing
data support the idea of a ductal progenitor-like cells giving
rise to hepatocytes (Furuyama et al., 2010; Huch et al., 2013),
there is also evidence that hepatocytes might give rise to cells
of the ductal lineage. For instance, periportal hepatocytes in pa-
tients with cholestatic or biliary autoimmune disorders canCell 157, 1324–1338, June 5, 2014 ª2014 Elsevier Inc. 1331
(legend on next page)
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express biliary-specificmarkers (Gouw et al., 2011). Additionally,
hepatocyte transplantation in the rat supports the possibility of
hepatocyte ‘‘transdifferentiation’’ into ductal cells (Michalopou-
los et al., 2005). More recently, lineage-tracing experiments
using AAV-Cre have demonstrated the capacity of adult hepato-
cytes to give rise to cells with morphological and molecular fea-
tures of biliary epithelial cells during injury (Yanger et al., 2013).
However, Malato et al. (2011) failed to observe hepatocyte-
derived contribution in a similar animal model. Other findings
have shown that dual NOTCH and AKT signaling in hepatocytes
can lead to their conversion into biliary cells that eventually prog-
ress into cholangiocarcinomas, a malignancy typically associ-
ated with a ductal origin (Fan et al., 2012; Komuta et al., 2012).
Our work here provides definitive evidence that adult hepato-
cytes have the potential to not only give rise to cells with ductal
characteristics but also cells that molecularly and functionally
resemble liver progenitors or ‘‘oval’’ cells. The observation that
a large proportion of hepatocytes (75%) undergo dedifferenti-
ation suggests that most hepatocytes intrinsically harbor this
developmental capacity. Thus, our studies raise the possibility
that hepatocytes are inherently plastic and might participate in
liver repair not only by self-duplication but also by dedifferentia-
tion into progenitor cells.
Our work reveals a unique role for Hippo/YAP signaling in liver
biology. The observed differential transcriptional output of YAP
between hepatocytes and progenitor cells suggests that
different YAP levels/activity could determine different hepatic
cell fates. Perhaps intermediate YAP levels would then specify
a differentiated ductal cell or cholangiocyte fate. This idea is sup-
ported by the finding of cholangiocyte hypoplasia in mice with a
developmental deletion of YAP in the liver (Zhang et al., 2010). In
this regard, it will be interesting to determine the mechanisms
that allow for robust YAP activation in a small subset of biliary
cells. Our data also show that NF2 is an important endogenous
regulator of YAP in hepatocytes. Previous work using a develop-
mental deletion of Nf2 in all liver cells demonstrated the
outgrowth of ductular cells and eventual development of cholan-
giocarcinoma (Benhamouche et al., 2010; Zhang et al., 2010).
These findings were interpreted as oval-cell expansion and
transformation driven by loss of Hippo signaling. Our findings,
alternatively, suggest that hepatocytes are the source of this
ductular outgrowth. Combined with recent findings (Fan et al.,Figure 5. YAP-Reprogrammed Progenitors Are Clonogenic and Produ
(A) Schematic representation of liver organoid generation from YAP Tg mice and
(B) Analysis of the number of organoids derived from livers from AAV-Cre-infec
dramatic increase of the liver organoid generation, both in the presence (ON) an
nofluorescent (IF) images of organoids in each category. Bars represent value of
(C) IF of wild-type (WT), ON Dox YAP Tg, and OFF Dox YAP Tg organoids for bil
(D) Hierarchical clustering analysis of primary hepatocytes, WT, and hepatocyte-d
(E) Differential expression analysis of hepatocytes compared to distinct orga
withR2.5 fold change.
(F) Experimental design for the isolation, expansion, and characterization of sing
(G) Representative image of organoid derived from single-sorted EYFP+ YAP Tg
(H) Differentiation of hepatocyte-derived organoid clone in the presence of g
demonstrate downregulation of biliary (CK19, SOX9, HNF1b) and increase of he
(I) Representative liver images 5months after transplantation of differentiated clon
(5x), and HNF4a (hepatocyte marker) and negative for CK19 (biliary marker).
See also Figure S4.2012; Sekiya and Suzuki, 2012; Zender et al., 2013), our work
argues in favor of a paradigm in which hepatocytes might be
the cell-of-origin not only for cholangiocarcinoma but also for
mixed-phenotype liver cancer, typically thought to arise from
oval cells.
Little is known about the identity of functional targets that act
downstream of YAP. NOTCH signaling has been shown to be
important for ductal specification during development (Hofmann
et al., 2010; Zong et al., 2009) and is also transiently activated
during liver regeneration (Ko¨hler et al., 2004). Our data demon-
strate that YAP/TEAD can directly control the expression of the
NOTCH2 receptor, likely regulating signaling. YAP/TEAD also
regulate Sox9 expression, itself a NOTCH target, suggesting
that YAP simply does not act upstream of NOTCH but that mul-
tiple layers of signaling crosstalk exist during progenitor/ductal
specification. Our clonal epistatic analysis using Rbpj-deficient
mice provides evidence indicating that NOTCH signaling is
important downstream of YAP for the outgrowth of YAP-driven
clones. NOTCH is also important, though not essential, for
some aspects of the fate-switching phenotype, such as upregu-
lation of cytokeratins and mesenchymal recruitment. NOTCH is
not required for the upregulation of other ductal/progenitor
markers, such as SOX9 and osteopontin (data not shown), sug-
gesting participation of other molecules downstream of YAP. It
has also been suggested that JAG1 can be a target of YAP in
hepatocellular carcinoma (Tschaharganeh et al., 2013). Although
other mechanisms downstream of YAP are likely at play, our ex-
periments suggest that YAP-driven tumors might benefit from
treatment with NOTCH inhibitors.
Our results demonstrate that tissue-specific progenitor cells
can be obtained from genetic manipulation of a mature cell
type in vivo. The extremely high efficiency and the rapid kinetics
of the dedifferentiation process suggest that this manipulation
might be used as a therapeutic strategy for inducing liver repair.
Transient inhibition of the Hippo kinases could be pursued to do
this. Because hepatocytes are relatively abundant, it is also
conceivable that these cells could be used for the generation
of progenitors cells ex vivo. Additionally, YAP activation confers
increased proliferative capacity and allows for monolayer growth
of progenitors initially grown in organoid-like cultures, facilitating
their maintenance, expandability in culture, and potential clinical
application. Together, our work lays the groundwork for thece Hepatocyte Progeny
expansion procedure.
ted Dox-uninduced (UI) and 3-week-induced YAP Tg mice. YAP Tg results in
d in the absence (OFF) of Dox in culture. Bottom shows representative immu-
n = 3.
iary (SOX9, CK19, HNF1b) and hepatocyte (HNF4a) markers.
erived YAP Tg organoids demonstrates close clustering of all organoid groups.
noid populations. Heatmap demonstrates all differentially expressed genes
le-cell hepatocyte-derived organoids.
cell, followed by monolayer expansion.
-secretase inhibitor and in the absence of Dox. Day 15 differentiated cells
patocyte markers (ALB, HNF4a).
al YAP-Tg cells into Fah/mice. Engrafted cells are positive for EYFP (5x), FAH
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Figure 6. YAP and TEAD Regulate Notch2 Transcription
(A) Quantitative real-time PCR analysis of NOTCHpathway genes from EYFP+-sorted uninduced and 1week Dox YAP Tg liver cells post-AAV-Cre infection. n = 3,
mean ± SEM.
(B) Immunofluorescent analysis for HES1 in an uninduced (Ctl) and a 2 week YAP Tg mouse. Dotted line outlines portal vein.
(C) ChIP-Seq binding profiles (reads per million per base pair) for TEAD4 at the Notch2 and Sox9 loci in trophoblast stem cells. Graph on the right shows ChIP-
PCR assays for the indicated validation sites (red boxes) performed in liver cells isolated from YAP Tg mice 2 weeks post-Dox. Graph on the right shows a
representative ChIP-PCR assay for the indicated validation sites (red boxes) performed in liver cells isolated from Yap Tg mice 2 weeks post-Dox. Mean ± SEM.
(D) Localization and sequence of TEAD binding sites (bold and underlined) present in the NOTCH2 promoter. Red box indicates area of genomic sequence (WT
Notch2 prom) that was cloned into a luciferase expression construct for functional analyses in CCLP1 cells (bottom). MutantNotch2 promoter construct contains
three mutated base pairs at each of the TEAD binding sites. n = 3, mean ± SEM.
(E) Quantitative real-time PCR analysis of the indicated target genes in Yapfl/fl Tazfl/fl liver organoids given either Adenovirus-EGFP or Ad-Cre:EGFP. mRNA
analysis of sorted infected cells was done 48 hr following infection. n = 3, mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S5.
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manipulation of Hippo pathway signaling for regenerative medi-
cine of liver disease. More broadly, our experiments suggest that
adult-differentiated epithelial cells could be manipulated for the
generation of tissue-specific progenitor or stem cells.
EXPERIMENTAL PROCEDURES
Full details are provided in the Extended Experimental Procedures.
Mouse Lines, AAV Virus Administration, Tamoxifen Induction, and
YAP Overexpression
FRG-NOD (Yecuris), tetracycline-inducible YAP expression (Camargo et al.,
2007), Ck19-CreERT2 (Means et al., 2008), conditional Rbpj (Han et al.,
2002), and Nf2 (Benhamouche et al., 2010) deletion mice are utilized in this
study. Ctgf-EGFP mice were derived from GENSAT. Male and female mice
were used in this study (except for microarray analysis) and did not show
sex-bias differences. AAV-TBG cre (University of Pennsylvania Vector Core,
AV-8-PV1091) was given to 4- to 8-week-old mice retro-orbitally. After
3 days, mice were administered doxycycline (1 mg/ml) ad libitum in their
cage water. For Ck19-CreERT mice, 4- to 8-week-old mice were given 3 mg
of tamoxifen for 5 sequential days. Two weeks later, doxycycline was started.
A minimum of three mice was examined per experiment. Conditional Rosa26
b-galactosidase, EYFP, and mT/mG mice were obtained from Jackson Labo-
ratory. All mouse procedures and protocols were approved by an AAALAC-ac-
credited facility.
Liver Organoid Growth Medium
Cultures were performed as described with slight modifications (Huch et al.,
2013). Liver organoid medium consists of Dulbecco’s modified Eagle’s
medium /F12 medium (Invitrogen), 13 N2-supplement (Invitrogen), 13 B27
without vitamin A-supplement (Invitrogen), 10 mM nicotinamide (Sigma-
Aldrich), 0.001 mM dexamethasone (Sigma-Aldrich), 10 mM HEPES (Invitro-
gen), and 20 mM Y27632 (Sigma-Aldrich). rmEGF (50 ng/ml; R&D Systems),
rmHGF (40 ng/ml; Peprotech), rmWnt3a (100 ng/ml; Peprotech), and rhRspo1
(500 ng/ml; R&D) were used as growth factor supplements. Growth factors
were replaced every other day, whereas fresh media was added every 4 days.
Liver Organoid Generation
Isolated livers from newborn or adult mice were mechanically diced and
digested. Filtered and pelleted cells were resuspended in ice-cold growth-
factor-reduced matrigel (BD Biosciences) with the growth factor cocktail.
Polymerization of cell/matrigel mixture was performed at 37C for 30 min,
followed by the addition of liver organoid growth medium. Liver organoid
colonies were observed at 7–10 days upon initial cell plating. To generate or-
ganoids from YAP Tg mice, YAP was induced for 3 weeks in the TetOYAP line,
and organoids were generated in ± Dox conditions.
Luciferase Assay
The indicated portion of the Notch2 promoter construct cloned into the pGL3-
Basic vector (Promega). At the two TEA binding sites identified within the
Notch2 promoter, three point mutations were generated at each site, and
this fragment was also cloned into the same vector. CCLP1 cells were cotrans-
fected with a Renilla plasmid and the constructs of interest. Cells were
harvested 72 hr later using the Dual-Glo Luciferase Assay System (Promega)
and assayed in accordance with the manufacturer’s directions.Figure 7. NOTCH Signaling Is a Functional Target of YAP/TEAD In Vivo
(A) Experimental design for hepatocyte-specific YAP overexpression with conco
(B) CK19 (green), GFP (red), and DAPI (blue) or JAG1 immunofluorescence (IF) in
and treated with Dox for 2 weeks. Bar graph shows quantitation of GFP+CK19+
(C) GFP stain of representative animals infected with low-dose AAV-Cre and trea
GFP+ cells per clone analyzed. n = 3, mean ± SEM.
(D) Representative IF triple stain (GFP, HNF4a, CK19) of single-cell-derived clones
proportion of clones displaying indicated markers. ***p < 0.001.
See also Figure S6.
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